ACR-ASTRO Practice Parameter for the Performance of Proton Beam Radiation Therapy.


Journal

American journal of clinical oncology
ISSN: 1537-453X
Titre abrégé: Am J Clin Oncol
Pays: United States
ID NLM: 8207754

Informations de publication

Date de publication:
03 2020
Historique:
pubmed: 7 2 2020
medline: 31 7 2020
entrez: 7 2 2020
Statut: ppublish

Résumé

The American College of Radiology (ACR) and the American Society for Radiation Oncology (ASTRO) have jointly developed the following practice parameter for proton beam radiation therapy. Proton radiotherapy is the application of a high-energy proton beam to a patient in a clinical setting with therapeutic intent. Proton radiotherapy may permit improved therapeutic ratios with lower doses to sensitive normal structures and greater dose to target tumor tissues. A literature search was performed to identify published articles regarding clinical outcomes, reviews, quality assurance methodologies, and guidelines and standards for proton radiation therapy. Selected articles are referenced in the text. The following recommendations are based on firsthand experiences of multiple clinical authorities who employ proton therapy and have been peer reviewed by experts at different practicing institutions. This practice parameter is developed to serve as a tool in the appropriate application of this evolving technology in the care of cancer patients or other patients with conditions where radiation therapy is indicated. It addresses clinical implementation of proton radiation therapy, including personnel qualifications, quality assurance standards, indications, and suggested documentation. This practice parameter is a tool to guide technical use of proton therapy and does not assess the relative clinical indication of proton radiotherapy when compared with other forms of radiotherapy, but to focus on the best practices required to deliver proton therapy safely and effectively, when clinically indicated. Costs of proton treatments are high, and the economic costs of proton radiotherapy may also need to be considered.

Sections du résumé

AIM/OBJECTIVES/BACKGROUND
The American College of Radiology (ACR) and the American Society for Radiation Oncology (ASTRO) have jointly developed the following practice parameter for proton beam radiation therapy. Proton radiotherapy is the application of a high-energy proton beam to a patient in a clinical setting with therapeutic intent. Proton radiotherapy may permit improved therapeutic ratios with lower doses to sensitive normal structures and greater dose to target tumor tissues.
METHODS
A literature search was performed to identify published articles regarding clinical outcomes, reviews, quality assurance methodologies, and guidelines and standards for proton radiation therapy. Selected articles are referenced in the text. The following recommendations are based on firsthand experiences of multiple clinical authorities who employ proton therapy and have been peer reviewed by experts at different practicing institutions.
RESULTS
This practice parameter is developed to serve as a tool in the appropriate application of this evolving technology in the care of cancer patients or other patients with conditions where radiation therapy is indicated. It addresses clinical implementation of proton radiation therapy, including personnel qualifications, quality assurance standards, indications, and suggested documentation.
CONCLUSIONS
This practice parameter is a tool to guide technical use of proton therapy and does not assess the relative clinical indication of proton radiotherapy when compared with other forms of radiotherapy, but to focus on the best practices required to deliver proton therapy safely and effectively, when clinically indicated. Costs of proton treatments are high, and the economic costs of proton radiotherapy may also need to be considered.

Identifiants

pubmed: 32028342
doi: 10.1097/COC.0000000000000672
pii: 00000421-202003000-00001
doi:

Types de publication

Journal Article Practice Guideline

Langues

eng

Sous-ensembles de citation

IM

Pagination

149-159

Références

Wilson RR. Radiological use of fast protons. Radiology. 1946;47:487–491.
Durante M, Loeffler JS. Charged particles in radiation oncology. Nat Rev Clin Oncol. 2010;7:37–43.
DeLaney TF. Proton therapy in the clinic. Front Radiat Ther Oncol. 2011;43:465–485.
Suit H. The Gray Lecture 2001: coming technical advances in radiation oncology. Int J Radiat Oncol Biol Phys. 2002;53:798–809.
Goitein M, Jermann M. The relative costs of proton and X-ray radiation therapy. Clin Oncol. 2003;15:S37–S50.
Steinberg ML, Konski A. Proton beam therapy and the convoluted pathway to incorporating emerging technology into routine medical care in the United States. Cancer J. 2009;15:333–338.
Lin LL, Vennarini S, Dimofte A, et al. Proton beam versus photon beam dose to the heart and left anterior descending artery for left-sided breast cancer. Acta Oncol. 2015;54:1032–1039.
Mailhot Vega RB, Kim J, Bussiere M, et al. Cost effectiveness of proton therapy compared with photon therapy in the management of pediatric medulloblastoma. Cancer. 2013;119:4299–4307.
Vogelius IR, Westerly DC, Aznar MC, et al. Estimated radiation pneumonitis risk after photon versus proton therapy alone or combined with chemotherapy for lung cancer. Acta Oncol. 2011;50:772–776.
Yock TI, Bhat S, Szymonifka J, et al. Quality of life outcomes in proton and photon treated pediatric brain tumor survivors. Radiother Oncol. 2014;113:89–94.
Yock TI, Yeap BY, Ebb DH, et al. Long-term toxic effects of proton radiotherapy for paediatric medulloblastoma: a phase 2 single-arm study. Lancet Oncol. 2016;17:287–298.
American College of Radiology. ACR–ASTRO practice parameter for radiation oncology 2014; Available at: https://www.acr.org/-/media/ACR/Files/Practice-Parameters/radonc.pdf. Accessed December 19, 2016.
American College of Radiology. ACR–AAPM technical standard for the performance of radiation oncology physics for external beam therapy 2015; Available at: https://www.acr.org/-/media/ACR/Files/Practice- Parameters/ext-beam-ts.pdf. Accessed December 19, 2016.
American College of Radiology. ACR–ASTRO practice parameter for image-guided radiation therapy (IGRT) 2014; Available at: https://www.acr.org/-/media/ACR/Files/Practice-Parameters/IGRT- RO.pdf?la=en. Accessed December 20, 2016.
American College of Radiology. ACR–AAPM technical standard for the performance of proton beam radiation therapy 2013; Available at: https://www.acr.org/-/media/ACR/Files/Technical-Standards/ProtonTherapy.pdf. Accessed December 19, 2016.
American College of Radiology. ACR–ASTRO practice parameter for communication: radiation oncology 2014; Available at: https://www.acr.org/-/media/ACR/Files/Practice-Parameters/Communication- RO.pdf. Accessed December 19, 2016.
American College of Radiology. Code of Ethics - Article XIII. 2016; Available at: https://www.acr.org/-/media/ACR/Files/Governance/Code-of-Ethics.pdf. Accessed September 20, 2017.
American Medical Association. Code of Medical Ethics. Available at: https://www.ama-assn.org/about-us/code-medical-ethics. Accessed December 19, 2016.
Dennis ER, Bussiere MR, Niemierko A, et al. A comparison of critical structure dose and toxicity risks in patients with low grade gliomas treated with IMRT versus proton radiation therapy. Technol Cancer Res Treat. 2013;12:1–9.
Douw L, Klein M, Fagel SS, et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. Lancet Neurol. 2009;8:810–818.
Barney CL, Brown AP, Grosshans DR, et al. Technique, outcomes, and acute toxicities in adults treated with proton beam craniospinal irradiation. Neuro Oncol. 2014;16:303–309.
Wattson DA, Tanguturi SK, Spiegel DY, et al. Outcomes of proton therapy for patients with functional pituitary adenomas. Int J Radiat Oncol Biol Phys. 2014;90:532–539.
Cheng YJ, Nie XY, Ji CC, et al. Long-term cardiovascular risk after radiotherapy in women with breast cancer. J Am Heart Assoc. 2017;6:pii: e005633.
Dess RT, Sun Y, Matuszak MM, et al. Cardiac events after radiation therapy: combined analysis of prospective multicenter trials for locally advanced non-small-cell lung cancer. J Clin Oncol. 2017;35:1395–1402.
Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013;368:987–998.
Baldini EH, Wang D, Haas RL, et al. Treatment Guidelines for Preoperative Radiation Therapy for Retroperitoneal Sarcoma: Preliminary Consensus of an International Expert Panel. Int J Radiat Oncol Biol Phys. 2015;92:602–612.
Tzeng CW, Fiveash JB, Popple RA, et al. Preoperative radiation therapy with selective dose escalation to the margin at risk for retroperitoneal sarcoma. Cancer. 2006;107:371–379.
DeLaney TF, Chen YL, Baldini EH, et al. Phase 1 trial of preoperative image guided intensity modulated proton radiation therapy with simultaneously integrated boost to the high risk margin for retroperitoneal sarcomas. Adv Radiat Oncol. 2017;2:85–93.
Wong P, Dickie C, Lee D, et al. Spatial and volumetric changes of retroperitoneal sarcomas during pre- operative radiotherapy. Radiother Oncol. 2014;112:308–313.
Scott MT, Todd KE, Oakley H, et al. Reducing anesthesia and health care cost through utilization of child life specialists in pediatric radiation oncology. Int J Radiat Oncol Biol Phys. 2016;96:401–405.
Romesser PB, Cahlon O, Scher ED, et al. Proton beam reirradiation for recurrent head and neck cancer: multi-institutional report on feasibility and early outcomes. Int J Radiat Oncol Biol Phys. 2016;95:386–395.
McDonald MW, Linton OR, Shah MV. Proton therapy for reirradiation of progressive or recurrent chordoma. Int J Radiat Oncol Biol Phys. 2013;87:1107–1114.
American College of Radiology. ACR practice parameter for continuing medical education (CME). 2017. Available at: https://www.acr.org/-/media/ACR/Files/Practice-Parameters/CME.pdf. Accessed December 19, 2016.
Huq MS, Fraass BA, Dunscombe PB, et al. Task Group No. 100 method for evaluating QA needs in radiation therapy. Med Phy (under review).

Auteurs

Helen A Shih (HA)

Massachusetts General Hospital & Harvard Medical School, Boston, MA.

Ramesh Rengan (R)

University of Washington, Seattle, WA.

Smith Apisarnthanarax (S)

University of Washington, Seattle, WA.

Chee-Wai Cheng (CW)

University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH.

Juliane Daartz (J)

Massachusetts General Hospital & Harvard Medical School, Boston, MA.

Thomas F DeLaney (TF)

Massachusetts General Hospital & Harvard Medical School, Boston, MA.

William F Hartsell (WF)

NM Chicago Proton Center/Radiation Oncology Consultants Ltd, Warrenville, IL.

Daniel J Indelicato (DJ)

University of Florida, Gainesville, FL.

Sameer R Keole (SR)

Mayo Clinic, Rochester, MN.

Seth Rosenthal (S)

Sutter Medical Group, Sacramento, CA.

Alan C Hartford (AC)

Dartmouth-Hitchcock Medical Center, Lebanon, NH.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH